Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 8/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 6/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 5/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.44 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12972289 | 1.00 | PTPN1 (0.47) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL26015705 | 0.93 | TLR2 (0.46) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL13225452 | 0.92 | TLR2 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL13696901 | 0.92 | TLR2 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL15674187 | 0.91 | PTPN1 (0.49) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL17807593 | 0.91 | MDM2 (0.45) | PTPN1SIRT2SIRT1SIRT3 | |
| SCHEMBL23253718 | 0.89 | PTPN1 (0.50) | PTPN1 | |
| SCHEMBL26015648 | 0.89 | PTPN1 (0.44) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL23286080 | 0.88 | PTPN1 (0.45) | PTPN1SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL16450347 | 0.88 | PTPN1 (0.48) | PTPN1SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524865-B2 | Antibodies and immunoconjugates and uses therefor | GENENTECH, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8309300-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2012-11-13 | — | — | US | disclosed |
| US-8088378-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENETECH INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-7855275-B2 | Cysteine engineered antibodies and conjugates | GENENTECH, INC. (US) | 2010-12-21 | — | — | US | disclosed |
| US-7723485-B2 | engineered by replacing one or more amino acids of a parent anti-MUC16 antibody with non cross-linked, reactive cysteine amino acids; Cys engineered anti-MUC16 antibodies (Ab) containing a heavy chain sequence, conjugated with one or more drug moieties through a linker; diagnostic and therapeutic uses | GENENTECH, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20100003766-A1 | screening cysteine engineered antibodies for thiol reactivity; using antibodies or antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor or cancer cells | GENENTECH, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-7521541-B2 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENETECH INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | GENENTECH, INC. | 2008-12-18 | — | — | US | disclosed |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-02-28 | — | — | US | disclosed |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | GENENTECH, INC. (US) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | PTPN1 2617/4885SIRT2 2275/4885SIRT1 3456/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | PTPN1 1939/4885SIRT2 4595/4885SIRT1 4869/4885 |
| US-20080311134-A1 | CYSTEINE ENGINEERED ANTI-MUC16 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | MUC1, PDIA6, LNPEP | PTPN1 1379/4885SIRT2 4495/4885SIRT1 4705/4885 |
| US-20090175865-A1 | using antibodies and antibody-drug conjugate compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions; killing or inhibiting the proliferation of tumor cells or cancer cells | ALB, LNPEP, CSTB | PTPN1 657/4885SIRT2 4316/4885SIRT1 4605/4885 |
| US-20070092940-A1 | A free cysteine amino acid is a cysteine residue which has been engineered into the parent antibody and is not part of a disulfide bridge; diagnostics and therapeutics; killing or inhibiting the proliferation of tumor cells or cancer cells | LNPEP, CSTB, ALB | PTPN1 536/4885SIRT2 4136/4885SIRT1 4602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.